Meta-analysis reveals a lack of association between MRP2 C-24T genetic polymorphism and the pharmacokinetics of mycophenolic acid in adult renal transplant recipients
We firstly assessed the effect of the multidrug resistance protein 2 (MRP2) C-24T polymorphism on the pharmacokinetics (PKs) and safety of mycophenolic acid (MPA) in the literature. MRP2 C-24T polymorphism has no significant effect on the PKs of MPA in steady-state conditions or the safety of MPA in adult renal transplant recipients; MRP2 C-24T polymorphism is not associated with the safety of MPA in adult renal transplant recipients; Further large-scale, case-control studies with rigorous designs should be carried out to confirm these conclusions.